reports
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
Solidt resultat for 1. kvartal 2025 på baggrund af god kundeaktivitet ...
Solidt resultat for 1. kvartal 2025 på baggrund af god kundeaktivitet på tværs af forretningen og stærk kreditkvalitet i et usikkert globalt miljø. Resultat efter skat på 5,8 mia. kr. Danske BankBernstorffsgade 401577 København VTlf. 45 14 14 002. maj 2025Side 1 af 3 Solidt resultat for 1. kvartal 2025 på baggrund af god kundeaktivitet på tværs af forretningen og stærk kreditkvalitet i et usikkert globalt miljøResultat efter skat på 5,8 mia. kr. Administrerende direktør Carsten Egeriis udtaler i forbindelse med regnskabet: ”Med resultatet for 1. kvartal 2025 fortsatte vi den tilfredsstil...
Solid results for the first quarter of 2025 driven by good customer ac...
Solid results for the first quarter of 2025 driven by good customer activity across the business and strong credit quality in an uncertain global environment. Net profit of DKK 5.8 billion. Press releaseDanske BankBernstorffsgade 40DK-1577 København VTel. 02 May 2025Page 1 of 3 Solid results for the first quarter of 2025 driven by good customer activity across the business and strong credit quality in an uncertain global environmentNet profit of DKK 5.8 billion. Carsten Egeriis, Chief Executive Officer, comments on the financial results: “For Danske Bank, the first quarter of 2025 was a ...
Storaktionærmeddelelse – Danske Bank A/S
Storaktionærmeddelelse – Danske Bank A/S Selskabsmeddelelse nr. 22 2025Danske BankBernstorffsgade 401577 København VTlf. 45 14 14 001. maj 2025Side 1 af 1 Storaktionærmeddelelse – Danske Bank A/S Med henvisning til § 31 i Lov om kapitalmarkeder oplyses det hermed, at Danske Bank pr. 25. april 2025, gennem direkte og indirekte besiddelser, rådede over 17.772.666 stemmerettigheder knyttet til aktier i Danske Bank A/S, svarende til 2,13 pct. af stemmerettighederne i Danske Bank A/S. Reduktionen af stemmerettigheder knyttet til aktier kan henføres til den kapitalnedsættelse, som blev beslutte...
Major shareholder announcement – Danske Bank A/S
Major shareholder announcement – Danske Bank A/S Company announcement no 22 2025Danske BankBernstorffsgade 40DK-1577 København VTel. 01 May 2025Page 1 of 1 Major shareholder announcement – Danske Bank A/S In accordance with section 31 of the Danish Capital Markets Act, we disclose that on 25 April 2025, Danske Bank held, through direct and indirect holdings, 17,772,666 voting rights attached to shares in Danske Bank A/S, corresponding to 2.13% of the total voting rights in Danske Bank A/S. The reduction of voting rights attached to shares can be attributed to the share capital reduction t...
- Rune Majlund Dahl
Novo Nordisk (Buy, TP: DKK900.00) - Underlying soft GLP-1 sales
We forecast a soft Q1, with 17.3% LCY sales growth and 13.8% LCY operating profit growth due to subdued prescriptions. While we estimate Ozempic sales c0.5% below consensus, we are c1.2% above for Wegovy, as we include DKK1bn in sales related to Wegovy US inventories. We see likely relief from potential unchanged 2025 LCY guidance, supported by improved Wegovy supply and fading pressure from compounders. We reiterate our BUY and DKK900 target price.
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- ABGSC Financials Research
- Fredrik Flørnes Støle
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
Electrolux AB: 3 directors
Three Directors at Electrolux AB bought 26,000 shares at between 58.588SEK and 60.240SEK. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over th...
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
Danske Bank AS: 1 director
A director at Danske Bank AS sold 117,008 shares at 227.770DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 30. april 2025 Indberetning nr. 30/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Pressechef, tel. Vedhæftet ...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 30 April 2025 Notification no. 30/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Ste...
- Rune Majlund Dahl
Zealand Pharma (Buy, TP: DKK1000.00) - Focus on pipeline progression
We expect an uneventful Q1 report, with investor focus on top-line results from the dapiglutide phase Ib obesity trial (due in Q2), which could help provide clarity on the positioning of the molecule in obesity and inflammation. For petrelintide, we have reduced our peak sales forecast to cUSD10.0bn (cUSD10.8bn) on increased competition from GUBamy. We reiterate our BUY but have cut our target price to DKK1,000 (1,150).
- Simen Mortensen
YIT (Sell, TP: EUR2.00) - 2025 guidance unchanged, we see EPS close to...
Q1 EBIT and EPS saw a healthy beat against our estimates and consensus, driven by a strong sales mix and internal efficiency gains. Unsold, completed apartments fell by 30% YOY, to their lowest level since Q3 2023. We have raised our 2025e EBIT, but do not see this as evidence of a broader recovery in Finnish residential markets. Our 2025e EBIT remains just above the guidance mid-point, with EPS hovering just below zero. We reiterate our SELL, but have raised our target price to EUR2 (1.75).
Danske Bank A/S, ledende medarbejderes transaktioner
Danske Bank A/S, ledende medarbejderes transaktioner 29. april 2025 Indberetning nr. 29/2025 Ændring i aktiebesiddelser hos Danske Banks indberetningspligtige i henhold til EU-forordningen om markedsmisbrug I forbindelse med Danske Bank A/S’ aktietilbagekøbsprogram sælger APMH Invest A/S løbende aktier i Danske Bank A/S pro rata. For yderligere detaljer henvises til de vedhæftede skemaer, hvori transaktioner udført af personer med ledelsesansvar og personer med nær tilknytning til disse skal indberettes og offentliggøres. Kontakt: Stefan Kailay Wind, Pressechef, tel. Vedhæftet ...
Danske Bank A/S, transactions by persons discharging managerial respon...
Danske Bank A/S, transactions by persons discharging managerial responsibilities 29 April 2025 Notification no. 29/2025 Transactions made by persons obliged to report transactions to the Danish FSA and Nasdaq Copenhagen, cf. the EU Market Abuse Regulation. In connection with the share buy-back program in Danske Bank A/S, APMH Invest A/S continuously sells shares pro rata. For further details, please find the attached templates for notifications and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them. Contact: Ste...
- ABGSC Financials Research
- Jan Erik Gjerland
- Magnus Andersson
- Patrik Brattelius
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.